Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. IV пересмотр (2009 год)

1. Lipid modification. National Institute for Health and Clinical Excellence. May 2008.

2. Recommendations for the use of LDL apheresis in the UK. Heart (UK) LDL Apheresis Working Group.

3. Christopher P. Cannon. Contemporary Cardioligy.

4. Familial Hypercholesterolemia, a global perspective. WHO. Report of second.

5. Thompson G., Morrell J., Wilson P. Dyslipidaemia in Clinical Practice.

6. Thompson G. R. A handbook of hyperlipidaemia. Current Science. Second Edition. 1994, P. 8.

7. Lipid Disorders. Kassianov G. Bestmedicine.

8. Sidney C. S., Jerilyn A., Steven N. B. et al. AHA / ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute.Circulation 2006; 113; 2363-2372.

9. Greenland P., Bonow P. O., Brundage B. H. et al. ACCF / AHA 2007 Clinical Expert Consensus Document on Coronary Artery Calcium Scoring By Computed Tomography in Global Cardiovascular Risk Assessment and in Evaluation of Patients With Chest Pain. JACC 2007; 49 (3) 378-402.

10. Hendel R. C. et al. ACCF / ACR/SCCT / SCMR / ASNC / NASCI / SCAI / SIR Appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J. Am. Coll. Cardiol. 2006; 48 (7): 1475-1497.

11. Bunce N. H., Pennell D. J. Magnetic resonance of coronary arteries. Eur Radiol. 2001; 11(5): 721-731.

12. Graham I., Atar D., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 2007; 14 Suppl 2: El-40.

13. Scanloni P. J., Faxon D. P., Audet A. M. et al. АСС / AHA Guidelines for Coronary Angiography. A Report of the American College of Cardiology / American Heart AssociationTask Force on Practice Guidelines (Committee on Coronary Angiography) JACC 1999; 33: 756-1824.

14. Gibbons R.J., Balady G.J., Beasley J.W. et al. АСС / AHA guidelines for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J. Am. Coll. Cardiol 1997; 30: 260-311.

15. Ritchie J.L., Bateman T.M., Bonow R.O. et al. Guidelines for clinical use of cardiac radionuclide imaging: report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J. Am. Coll. Cardiol. 1995; 25: 521-47.

16. Cheitlin M. D., Alpert J. S., Armstrong W. F. et al. ACC / AHA guidelines for the clinical application of echocardiography: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography), developed in collaboration with the American Society of Echocardiography. Circulation 1997; 95: 1686-744.

17. Pitt B., Mancini G. B., Ellis S. G., Rosman H. S., Park J. S., McGoven M. E. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): reduction in atherosclerosis progression and finical events. JACC. 1995; 26: 1113-1145.

18. Taylor A. J., Sullenberger L. E., Lee H. J., Lee J. K., Grace K. A. ARBITER-II: a double-blind, placebocontrolled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004; Dec 7; 110 (23) : 3512-7. Epub 2004 Nov 10.

19. JUPITER Study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-densitylipoprotein cholesterol and elevated high-sensitivity C-reactiveprotein:rationale and design of the JUPITER trial. Circulation. 2003; 108: 2292-2297.

20. Thompson G. R., Lowenthal R., Myant R. Plasma exchange in management of homozygous familial hypercholesterolemia. Lancet 1975, 1, 1208-11.

21. Thompson G. R., Myant N. B., Kilpatrick D., Oakley C. M., Raphael M. G., Steiner R. E. Assessment of long-term plasma exchange for familial hypercholesterolemia. Br. Heart. J. 1980, 43, 680-8.

22. Thompson G. R., Miller J. P., Breslow J. L. Improved survival of patients with ho-mozygous familial hypercholesterolemia treated by plasma exchange. Br. Med. J. 1985, 291, 1671-3.

23. Kroon A. A., Aengevaeren W. R., van der Werf T. et al. LDL-apheresis Atherosclerosis Regression Study (LAARS). Effect of ag gressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996; 93: 1826-35.

24. Blackburn D. F., Dobson R. T., Blackburn J. L., Wilson T. W. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005; 25 (8): 1035-43.

25. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003.

26. Schedlbauer A., Schroeder K., Fahey T. How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials. Fam Pract 2007; 24: 380-387.

27. McKenney J. M. et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 2006; 97: 89C-94C.

28. Bays H. Statin safety: an overview and assessment of the data—2005. Am. J. Cardiol. 2006;97:6C-26C.

29. Vaughan C. J. et al. Update on statins: 2003. Circulation,2004; 110: 886-892.

30. Law M., Rudnicka A. R. Statin safety: a systematic review. Am. J. Cardiol. 2006; 97: 52C-60C.

31. Gotto A. M. Jr. Statins, cardiovascular disease, and drug safety. Am. J. Cardiol. 2006; 97: 3C-5C

32. Thompson P. D. et al. An assessment of statin safety by muscle experts. Am. J. Cardiol. 2006; 97: 69C-76C.

33. Despres J. et al. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J. Intern. Med. 2002: 490-499.

34. Feher M. D., Caslake M., Foxton J. et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with nticro-nised fenofibrate. Diabetes Metab Res.Rev 1999; 15: 395-99.

35. Steinmetz A. et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. J. Cardiovasc. Pharmacol., 1996; 27: 563-570.

36. Mikhailides D. P. et al. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int. Angiol. 1998; 17: 225-33.

37. Baskes L. M. et al. Fibrates: what have we learned in the past 40 years? Pharmacotherapy. 2007; 27 (3): 412-24.

38. Evans M., Anderson R. A., Graham J. et al. Ciprofibrate therapy improves en-dothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000 Apr 18; 101 (15): 1773-9

39. M. J. Chapman Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13.

40. Elisaf M. Effects of fibrates on serum metabolic parameters. Current. Med. Res. Opinion. 2002; 18 (5): 269-276.

41. Keating G. M., Croom K. F. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs. 2007; 67 (1): 121-153.

42. Heart Protection Study (HPS)Collaborativ Group. MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963people with diabetes. Lancet 2003; 361 (14): 2005-16.

43. Russell S. et al. Diabetes Care Publish Ahead of Print published online ahead of print November 4, 2008.

44. Drugs, Fenofibrate, 2007; 67 (1): 121-153.

45. Stone N., Blum C., Winslow E. Management of Lipids in Clinical Practice. 1997.

46. Calo L. et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J. Am. Coll. Card. 2005; 45: 1723-8

47. Davidson M. N. et al. 1 Am Coll. Cardiol. 2002; 40: 2125-34

48. Famier M. Eur Heart J. 2007; 153(2): 335el-8.

49. Kastelein J., Akdim F. et al. Simvastatin with or with-out ezetimibe in familial hy-percholesterolaemia. New Engl. J. Med. 2008; 358: 1431-43.

50. Knapp H. H. et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholestero-lemia. Am. J. Med 2001; 110: 352-360.

51. Tsai C. H. et al. J. Clin. Biochemistry and Nutrition 1995; 19 (2): 115-121.

52. Tonstad S. et al. Effectiveness of low-dose lovastatin combined with low-dose colestipol in moderate to severe primary hypercholesterolaemia. Scan. J. Clin. Lab. Invest. 1993; Aug; 53 (5): 457-63

53. Grundy S. M., Vega G. L., Yuan Z. et al. Effectiveness and tolerability of simvsatatin plus fenofibrate for combined hyperlipideamia (the SAFARI trial). Am. J. Cardiol. 2006; 98 (3): 427-8).

54. Durrington P. N., Tuomilehto J., Hamann A. et al. Rosuvastatin and fenofibrate alone and in combination in type 2 dibetes patient with combined hyperlipidaemia. Diabetes. Res. Clin. Practice. 2004; 64 (2): 137-51

55. Singh I. M. et al. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007: 298: 786-798.

56. Brown B. G., Zhao X. Q., Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001; 345: 1583-592.

57. Taylor A. J., Sullenberger L. E., Lee H. J. et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-con trolled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004; 110: 3512-3517).